Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK. Mauriac L, et al. Among authors: pippen je. Eur J Cancer. 2003 Jun;39(9):1228-33. doi: 10.1016/s0959-8049(03)00199-0. Eur J Cancer. 2003. PMID: 12763210 Clinical Trial.
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA. Robertson JF, et al. Among authors: pippen j. Clin Pharmacokinet. 2004;43(8):529-38. doi: 10.2165/00003088-200443080-00003. Clin Pharmacokinet. 2004. PMID: 15170367 Clinical Trial.
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Osborne CK, et al. Among authors: pippen j. J Clin Oncol. 2002 Aug 15;20(16):3386-95. doi: 10.1200/JCO.2002.10.058. J Clin Oncol. 2002. PMID: 12177098 Clinical Trial.
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, Pippen J, Patel M, Paul D, Blum JL, Holmes FA, Myron MC, Cantrell J, Hartung NL, Look RM, Di Salle E, Davis JC, Ilegbodu D, Asmar L. Jones S, et al. Among authors: pippen j. Clin Breast Cancer. 2008 Dec;8(6):527-32. doi: 10.3816/CBC.2008.n.065. Clin Breast Cancer. 2008. PMID: 19073509 Clinical Trial.
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
Jones SE, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, Blum J, Kirby R, Stone M, Pippen J, George T, Orr D, Knox S, Grant M, Peters G, Savino D, Rietz C. Jones SE, et al. Among authors: pippen j. Clin Breast Cancer. 2002 Jun;3(2):147-52. doi: 10.3816/CBC.2002.n.019. Clin Breast Cancer. 2002. PMID: 12123539 Clinical Trial.
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz C. Jones S, et al. Among authors: pippen j. Clin Breast Cancer. 2001 Jan;1(4):310-4; discussion 315-7. doi: 10.3816/CBC.2001.n.005. Clin Breast Cancer. 2001. PMID: 11899353
57 results